

Press Release - March 29, 2019

Invivo Ventures FCR, a new venture capital fund in the biomedical sector

Invivo Ventures FCR is launched with a committed capital of 40M in its first closing and aims to invest in companies in the field of life sciences. Invivo intends to support projects in their initial stages with a special emphasis on technology transfer from research centers, hospitals and universities.

Invivo, headquartered in Barcelona, will focus primarily on the Spanish market where there is a growing volume of entrepreneurial initiatives in the field of healthcare innovation but a shortage of financial resources for their successful development at early clinical. Invivo aims to make around 12 investments.

The fund is participated by a majority of private investors and has the support of several institutional investors such Fond-ICO Global and the Institut Català de Finances. Furthermore, Invivo is supported by InnovFin Equity with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (EFSI) set up under the Investment Plan for Europe. The purpose of EFSI is to help support financing and implementing productive investments in the European Union and to ensure increased access to financing.

Invivo Ventures will be managed by Invivo Capital Partners, a management company founded by Dr. Lluís Pareras and Albert Ferrer. Both managers have extensive experience in the sector. In recent years they have been managing the venture capital company Healthequity SCR.

Healthequity has participated in projects such as Minoryx, Sanifit, Versantis and Peptomyc that have raised significant capital rounds from national and international investors. Healthequity is in the disinvestment phase and both directors will continue to manage the portfolio of investees.

